1
|
Development of a chiral micellar electrokinetic chromatography-tandem mass spectrometry assay for simultaneous analysis of warfarin and hydroxywarfarin metabolites: application to the analysis of patients serum samples. J Chromatogr A 2012; 1271:207-16. [PMID: 23246089 DOI: 10.1016/j.chroma.2012.11.046] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2012] [Revised: 11/14/2012] [Accepted: 11/19/2012] [Indexed: 11/22/2022]
Abstract
The enantioseparation of warfarin (WAR) along with the five positional and optical isomers is challenging because of the difficulty to simultaneously separate and quantitate these chiral compounds. Currently, no effective chiral CE-MS methods exist for the simultaneous enantioseparation of WAR and all its hydroxylated metabolites in a single run. Polymeric surfactants (aka. molecular micelles) are particularly compatible with micellar electrokinetic chromatography-mass spectrometry (MEKC-MS) because they have a wider elution window for enantioseparation and do not interfere with the MS detection of chiral drugs. Using polysodium N-undecenoyl-L,L-leucylvalinate (poly-L,L-SULV) as a chiral pseudophase in MEKC-MS baseline separation of WAR, its five metabolites along with the internal standard was obtained in 45 min. This is in comparison to 100 min required for separation of the same mixture with packed column CEC-MS using a vancomycin chiral stationary phase. Serum samples were extracted with mixed-mode anion-exchange (MAX) cartridge with recoveries of greater than 85.2% for all WAR and hydroxywarfarin (OH-WAR) metabolites. Utilizing the tandem MS and multiple reaction monitoring mode, the MEKC-MS/MS method was used to simultaneously generate calibration curves over a concentration range from 2 to 5000 ng/mL for R- and S-warfarin, 5 to 1000 ng/mL for R- and S-6-, 7-, 8- and 10-OH-WAR and 10 to 1000 ng/mL for R and S-4'-OH-WAR. For the first time, the limits of detection and quantitation for most WAR metabolites by MEKC-MS/MS were found to be at levels of 2 and 5 ng/mL, respectively. The method was successfully applied for the first time to analyze WAR and its metabolites in plasma samples of 55 patients undergoing WAR therapy, demonstrating the potential of chiral MEKC-MS/MS method to accurately quantitate with high sensitivity.
Collapse
|
2
|
Radwan MA, Bawazeer GA, Aloudah NM, AlQuadeib BT, Aboul-Enein HY. Determination of free and total warfarin concentrations in plasma using UPLC MS/MS and its application to a patient samples. Biomed Chromatogr 2011; 26:6-11. [DOI: 10.1002/bmc.1616] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2010] [Accepted: 01/11/2011] [Indexed: 11/09/2022]
Affiliation(s)
- Mahasen A. Radwan
- Department of Clinical Pharmacy; King Saud University; PO Box 22452; Riyadh; 11495; Saudi Arabia
| | - Ghada A. Bawazeer
- Department of Clinical Pharmacy; King Saud University; PO Box 22452; Riyadh; 11495; Saudi Arabia
| | - Nouf M. Aloudah
- Department of Clinical Pharmacy; King Saud University; PO Box 22452; Riyadh; 11495; Saudi Arabia
| | - Bushra T. AlQuadeib
- Department of Pharmaceutics; College of Pharmacy; King Saud University; PO Box 22452; Riyadh; 11495; Saudi Arabia
| | - Hassan Y. Aboul-Enein
- Pharmaceutical and Medicinal Chemistry Department; Pharmaceutical and Drug Industries Research Division; National Research Centre; Dokki; Cairo; 12311; Egypt
| |
Collapse
|
3
|
Wright DFB, Duffull SB. Development of a bayesian forecasting method for warfarin dose individualization. Pharm Res 2011; 28:1100-11. [PMID: 21301936 DOI: 10.1007/s11095-011-0369-x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Accepted: 01/10/2011] [Indexed: 12/17/2022]
Abstract
PURPOSE The aim of this study was to develop a Bayesian dose individualization tool for warfarin. This was incorporated into the freely available software TCIWorks ( www.tciworks.info ) for use in the clinic. METHODS All pharmacokinetic and pharmacodynamic (PKPD) models for warfarin in the medical literature were identified and evaluated against two warfarin datasets. The model with the best external validity was used to develop an optimal design for Bayesian parameter control. The performance of this design was evaluated using simulation-estimation techniques. Finally, the model was implemented in TCIWorks. RESULTS A recently published warfarin KPD model was found to provide the best fit for the two external datasets. Optimal sampling days within the first 14 days of therapy were found to be days 3, 4, 5, 11, 12, 13 and 14. Simulations and parameter estimations suggested that the design will provide stable estimates of warfarin clearance and EC50. A single patient example showed the potential clinical utility of the method in TCIWorks. CONCLUSIONS A Bayesian dose individualization tool for warfarin was developed. Future research to assess the predictive performance of the tool in warfarin patients is required.
Collapse
Affiliation(s)
- Daniel F B Wright
- School of Pharmacy, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
| | | |
Collapse
|
4
|
Costa I, Serralheiro A, Rodrigues M, Alves G, Falcão A. Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy. Biomed Pharmacother 2010; 64:130-2. [DOI: 10.1016/j.biopha.2009.09.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2009] [Accepted: 09/01/2009] [Indexed: 10/20/2022] Open
|
5
|
Pitsiu M, Parker EM, Aarons L, Rowland M. A Bayesian method based on clotting factor activity for the prediction of maintenance warfarin dosage regimens. Ther Drug Monit 2003; 25:36-40. [PMID: 12548142 DOI: 10.1097/00007691-200302000-00005] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
A Bayesian algorithm, employing a population pharmacokinetic-pharmacodynamic model, for the effective and rapid prediction of warfarin maintenance dosing requirements was developed. The algorithm was evaluated prospectively in five healthy volunteers who were given a 15-mg single dose of racemic warfarin. Based on previous population pharmacokinetic and pharmacodynamic parameters and factor VII response measurements taken during the first 48 hours, dosage regimens to achieve a subtherapeutic degree of anticoagulation (50% of normal) were determined. Three factor VII response measurements were sufficient to determine dosing requirements in the five volunteers. The advantage of the algorithm is that it does not require warfarin concentration measurements and uses non-steady-state data.
Collapse
Affiliation(s)
- Maria Pitsiu
- School of Pharmacy and Pharmaceutical Sciences, University of Manchester, United Kingdom
| | | | | | | |
Collapse
|
6
|
Costa IM, Soares PJ, Afonso M, Ratado P, Lanaot JM, Falcão AC. Therapeutic monitoring of warfarin: the appropriate response marker. J Pharm Pharmacol 2000; 52:1405-10. [PMID: 11186249 DOI: 10.1211/0022357001777405] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Warfarin is a 4-hydroxycoumarin anticoagulant drug used for the prevention and management of thromboembolic and vascular diseases. It acts through the inhibition of the vitamin K-dependent transcarboxylation reactions that convert precursors of clotting factors into their active form. Appropriate use of warfarin requires patient monitoring and dosage adjustments, to ensure its safety and efficacy. The aim of this work was to clarify the relationship between traditional (prothrombin time, usually expressed as the international normalized ratio; INR) and alternative (clotting factors II and X) warfarin response markers to establish their usefulness for therapeutic drug monitoring. Seventy adult outpatients, aged between 31 and 86 years old, were involved in the study. All subjects received warfarin in a monotherapy regimen and had been on a stable dosing schedule for at least two weeks to assure a steady-state condition. A total of 81 prothrombin times (expressed as INR), and factor II and factor X activity were simultaneously determined. Eleven patients presented repeated measurements at different time periods under the same dosing regimen. The results obtained from regression and cluster analysis showed a close relationship between factors II and X (r = 0.73), a weak correlation between INR and both factor II (r = -0.35) and factor X (r = -0.36), and a very slight dependency between warfarin and the response markers used. In addition, it seems that independent of the selected response marker, in long-term warfarin therapy, reproducible responses can be obtained over time if a steady-state condition is achieved. The coefficients of variation for factors II and X were greater (35.44 and 37.93%, respectively) than INR (14.50%), indicating that INR is a more precise measure than either factor II or factor X. In conclusion, INR appears to be the most appropriate warfarin response marker for therapeutic drug monitoring due to its universality, objectivity as a direct physiological effect measurement, and the available information regarding appropriate endpoints. However, when INR values are not in accordance with patient response therapy, factor II and factor X should be considered as an alternative to optimize warfarin therapy.
Collapse
Affiliation(s)
- I M Costa
- Faculty of Pharmacy, University of Coimbra, Portugal
| | | | | | | | | | | |
Collapse
|
7
|
Abstract
We assessed the ability of a graphic nomogram to adjust steady-state warfarin dosages and to predict international normalized ratios (INR) after a dosage change, compared with an anticoagulation clinic pharmacist and a Bayesian regression computer program. Study subjects were 108 men and 3 women receiving warfarin anticoagulation. In all patients the median absolute errors in predicted INR values for the nomogram, computer program, and pharmacist were 0.33, 0.46, and 0.48, respectively. The nomogram was significantly more precise than both other methods (p=0.036). In a subset of 50 patients who required dosage reductions, the median absolute INR prediction errors for the nomogram, computer program, and pharmacist were 0.35, 0.54, and 0.48 respectively. The nomogram was significantly more precise than the pharmacist (p=0.005) and computer (p=0.002). The ability to provide more precise dosage reductions of warfarin may be of clinical importance in light of current recommendations for higher-intensity warfarin therapy and maintenance of higher INR values. Prospective validation of the performance of this nomogram in a routine clinical setting is warranted.
Collapse
Affiliation(s)
- G M Dalere
- Department of Pharmacy, Kaiser Permanente Medical Center, Santa Clara, California, USA
| | | | | |
Collapse
|
8
|
Comets E, Mentré F, Pousset F, Diquet B, Montalescot G, Ankri A, Mallet A, Lechat P. Modeling INR data to predict maintenance fluindione dosage. Ther Drug Monit 1998; 20:631-9. [PMID: 9853979 DOI: 10.1097/00007691-199812000-00009] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This study was designed to construct a pharmacokinetic/pharmacodynamic model describing the evolution of International Normalized Ratio (INR) under oral anticoagulation treatment by fluindione in patients and to develop a method for individualization of fluindione dosage. Three indirect response models describing the concentration-INR relationship were tested using a nonparametric estimation method. INR was modelled as a quantity being produced and eliminated. According to a log-likelihood ratio test, the evolution of INR was best modelled as an inhibition of its elimination by fluindione. The selected model was evaluated in 24 additional patients with INR measurements (after 2, 3, 4, 6, and 10 doses). Using a Bayesian method with data until day 4, INR was correctly predicted for days 6 and 10. The population characteristics of fluindione were estimated, pooling the two groups of patients. A Bayesian method for individualization of dosage regimen was developed, based on a risk function for INR at steady state. Prescription rules for fluindione were derived using this method retrospectively on the 73 patients in this study.
Collapse
Affiliation(s)
- E Comets
- INSERM U436, Modélisation Mathématique et Statistique en Biologie et Médecine, Institut de Physiopathologie et de Génétique Cardiovasculaire, Centre Hôpital Universitaire Pitié-Salpêtrière, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Mentré F, Pousset F, Comets E, Plaud B, Diquet B, Montalescot G, Ankri A, Mallet A, Lechat P. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther 1998; 63:64-78. [PMID: 9465843 DOI: 10.1016/s0009-9236(98)90122-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Fluindione is a vitamin K antagonist with a long half-life. This study was designed to investigate the pharmacokinetics and pharmacodynamics of multiple doses of fluindione in patients. METHODS In a learning group of 49 patients who began fluindione treatment, blood samples were taken 12, 18, or 24 hours after one, three, and five doses. Concentration of fluindione, activity of clotting factors II, VII, IX and X, prothrombin complex activity (PCA), and international normalized ratio (INR) were measured. An indirect-response pharmacodynamic model was used for each effect. A comprehensive analysis was performed with a nonparametric population approach. The model was evaluated in 24 other patients: blood samples were taken 24 hours after two, three, four, and six doses; and PCA and INR were observed. RESULTS Analysis of concentrations and clotting factor activities showed notably that (1) fluindione has a long half-life (median, 69 hours), and (2) concentration that inhibits the synthesis of the clotting factors by 50% varied for each factor, with a median ranging from 0.25 to 2.05 mg.L-1 for factors VII and II, respectively. The results obtained for INR and PCA were validated in the 24 subsequent patients. CONCLUSION The population approach allowed the comparison of several pharmacodynamic submodels. This first application of the indirect-response model to multiple oral anticoagulant doses in patients confirmed that both the pharmacokinetics and the pharmacodynamics of fluindione show substantial interindividual variability.
Collapse
Affiliation(s)
- F Mentré
- INSERM U436, Génétique Cardiovasculaire Centre Hospitalo-Universitaire Pitié-Salpêtrière, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
White RH, Zhou H, Romano P, Mungall D. Changes in plasma warfarin levels and variations in steady-state prothrombin times. Clin Pharmacol Ther 1995; 58:588-93. [PMID: 7586953 DOI: 10.1016/0009-9236(95)90179-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
OBJECTIVE To determine the relative contribution of changes in the plasma warfarin level to variation in the serial steady-state prothrombin times. METHODS This was a prospective observational cohort study performed at two outpatient anticoagulation clinics. Serial prothrombin times and paired plasma total warfarin levels were determined in a convenience sample of otherwise healthy patients who required long-term oral anticoagulation therapy with warfarin. RESULTS Serial measurements were obtained from 129 patients, 60 of whom provided three or more serial samples. Analysis of covariance showed a highly significant (p = 0.0001) relationship between the anticoagulant effect and the logarithm of the warfarin concentration (R2 = 0.75), with 15.3% of the total variance attributable to the effect of warfarin and 31.1% attributable to individual variation in sensitivity to warfarin. In an analysis of the subjects who had three or more serial measurements, the mean weighted correlation coefficient for the relationship between the logarithm of the warfarin concentration and the anticoagulant response varied widely, from strongly negative to strongly positive, and as the range of observed prothrombin times increased, stronger positive correlation was observed. CONCLUSIONS In this cohort, the plasma warfarin level was a strong predictor of observed changes in serial prothrombin time measurements. However, the correlation between clotting times and warfarin levels varied widely among subjects, particularly when the range of observed prothrombin times was moderate. This suggests that in these subjects, other factors, such as measurement error or pharmacodynamic changes, played a major role.
Collapse
Affiliation(s)
- R H White
- University of California, Davis, USA
| | | | | | | |
Collapse
|
11
|
Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994; 37:563-9. [PMID: 7917775 PMCID: PMC1364816 DOI: 10.1111/j.1365-2125.1994.tb04305.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
1. The disposition of warfarin enantiomers and metabolites has been studied in 36 patients receiving chronic rac-warfarin therapy, titrated to approximately the same anticoagulant response. 2. A stereoselective h.p.l.c. assay was employed to determine the concentrations of (R)- and (S)-warfarin, (R,S)-warfarin alcohol and (S)-7-hydroxywarfarin in plasma and 24 h urine samples. The concentrations of (R)-7-hydroxywarfarin, (S,S)-warfarin alcohol and (R)-6- and (S)-6-hydroxywarfarin were also determined in urine samples. The fractions unbound of warfarin enantiomers were determined using equilibrium dialysis. 3. Wide variability was observed in daily dose requirements (mean 6.1 mg; range: 2.5-12 mg), in plasma concentrations of (S)-warfarin (0.48 mg l(-1); 0.11-1.02 mg l(-1)), (R)-warfarin (0.87 mg l(-1); 0.29-1.82 mg l(-1)), (R,S)-warfarin alcohol (0.31 mg l(-1); 0.02-0.72 mg l(-1)) and (S)-7-hydroxywarfarin (0.25 mg l(-1); 0.07-0.37 mg l(-1)) and the percentage unbound of (S)-warfarin (0.53%; 0.29%-0.82%) and (R)-warfarin (0.54%; 0.26%-0.96%). 4. The mean plasma clearances of warfarin enantiomers were 7.5 1 day-1 per 70 kg (2.5-22.1) for (S)-warfarin and 3.6 1 day-1 per 70 kg (1.6-8.8) for (R)-warfarin. There was a significant correlation between the estimated formation clearance of (S)-7-hydroxywarfarin and the clearance of (S)-warfarin, which accounted for much of the variability in the latter.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- E Chan
- Department of Pharmacy, University of Manchester, UK
| | | | | | | | | | | |
Collapse
|
12
|
Abstract
The widespread application of Bayesian parameter estimation in the area of therapeutic drug monitoring (TDM) has prompted the need for well conducted population studies to obtain relevant prior pharmacokinetic parameter estimates. In many cases the population has consisted of a relatively small number of subjects. This may be unavoidable for drugs used in cancer chemotherapy or in small, specific populations of patients. In contrast, information about drugs which are used extensively, such as the aminoglycosides, can be obtained by population studies which involve a large number of individuals. Indeed, this technique has proved particularly useful for determining parameter estimates which can be employed in neonatal TDM. Bayesian parameter estimation has been most frequently used for drugs with narrow therapeutic ranges such as the aminoglycosides, cyclosporin, digoxin, anticonvulsants (especially phenytoin), lithium and theophylline. However, the technique has now been extended to cytotoxic drugs, Factor VIII and warfarin. Bayesian methods have also been used to limit the number of samples required in more conventional pharmacokinetic studies with new drugs. Further advances in the use of these methods are likely to include measures of drug response and toxicity requiring population studies which also include relevant pharmacodynamic information.
Collapse
Affiliation(s)
- A H Thomson
- Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, Scotland
| | | |
Collapse
|
13
|
Richmond RG, Sawyer WT, Aiello PD, Lindley CM. Extreme warfarin intoxication secondary to possible covert drug ingestion. DRUG INTELLIGENCE & CLINICAL PHARMACY 1988; 22:696-9. [PMID: 3215113 DOI: 10.1177/106002808802200910] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
A young adult male patient presented with an excessively prolonged prothrombin time (greater than 90 sec) following approximately two weeks of therapy with oral warfarin sodium, in doses between 2.5 and 5 mg/d. Repeated administration of vitamin K and fresh frozen plasma was required to reverse the anticoagulation and maintain a normalized prothrombin time. Serial warfarin plasma concentration measurements were used to interpret the apparently unusual prothrombin time response profile and to detect the possibility of covert drug ingestion.
Collapse
|